Parkinson Disease

Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics

Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics

By

People with multiple system atrophy and progressive supranuclear palsy had the shortest life expectancy, with a mortality rate that was more than 3 times higher than for the general population.

Parkinson Disease Treatment Soon to Be Discontinued

Parkinson Disease Treatment Soon to Be Discontinued

By

Requip and Requip XL are non-ergot dopamine agonists indicated for the treatment of Parkinson disease.

Levodopa Inhalation Powder Approved for Parkinson Disease

Levodopa Inhalation Powder Approved for Parkinson Disease

By

Inbrija is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson disease taking carbidopa/levodopa.

Age Independently Associated With Severity of Executive Dysfunctions in Parkinson Disease

Age Independently Associated With Severity of Executive Dysfunctions in Parkinson Disease

By

Age at Parkinson disease onset is independently associated with the performance of executive functions.

Reduced Survival for Patients With Idiopathic Parkinsonism

Reduced Survival for Patients With Idiopathic Parkinsonism

Patients with idiopathic parkinsonism have reduced survival, although survival is dependent on the type and characteristics of the parkinsonian disorder.

Removing Appendix May Lower Risk for Parkinson Disease

Removing Appendix May Lower Risk for Parkinson Disease

The normal human appendix seems to contain pathogenic forms of α-synuclein, which may impact the risk for developing Parkinson disease.

Type 2 Diabetes May Have Adverse Effect on Parkinson Disease Symptoms, Outcomes

Type 2 Diabetes May Have Adverse Effect on Parkinson Disease Symptoms, Outcomes

By

Patients with both Parkinson disease and type 2 diabetes were more likely to have cardiovascular comorbidities than those with only Parkinson disease.

REM Sleep Behavior Disorder Associated With Worse Cognitive Performance in PD-Susceptible Patients

REM Sleep Behavior Disorder Associated With Worse Cognitive Performance in PD-Susceptible Patients

By

Participants in the RBD group had significantly worse performances on the Symbol Digit Modality Test compared with participants in the hyposmia and NMC cohorts.

Gout Linked to Higher Risk for Incident Parkinson Disease in Older Adults

Gout Linked to Higher Risk for Incident Parkinson Disease in Older Adults

By

Gout may be associated with a higher risk for incident PD in older adults.

Half of Women to Develop Stroke, Dementia, or Parkinsonism

Half of Women to Develop Stroke, Dementia, or Parkinsonism

One in two women and one in three men will develop dementia, stroke, or parkinsonism during their lifetime.

Gocovri Treatment Effect Maintained for up to 2 Years in PD Patients With Dyskinesia

Gocovri Treatment Effect Maintained for up to 2 Years in PD Patients With Dyskinesia

By

The open-label safety study included patients from 3 Gocovri dyskinesia efficacy trials (N=223) and evaluated the long-term safety and tolerability of the treatment.

Do β2‐Adrenoreceptor Medications Affect Parkinson Disease Risk?

Do β2‐Adrenoreceptor Medications Affect Parkinson Disease Risk?

By

In order to determine the risk of PD associated with various β2‐adrenoreceptor drugs, the study authors assessed United States Medicare beneficiary data from 2009.

Reverse Nocturnal BP Dipping Identifies Cardiovascular Dysautonomia in Parkinson Disease

Reverse Nocturnal BP Dipping Identifies Cardiovascular Dysautonomia in Parkinson Disease

By

A greater proportion of patients with dysautonomia had supine hypertension compared with patients without dysautonomia.

FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid

FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid

By

Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.

Loss of Function Variants in <i>LRRK1</i> and <i>LRRK2</i> Not Linked to Parkinson Disease

Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease

By

Kinase inhibition or allele-specific targeting of mutant LRRK2 may still be a meaningful target for therapeutic development.

Sensor Array May Detect De Novo Parkinson's Disease in Breath

Sensor Array May Detect De Novo Parkinson's Disease in Breath

A sensor array has the potential to identify de novo Parkinson's disease (PD) patients with high sensitivity, specificity, and accuracy values.

Repetitive TMS for Parkinson Disease Depression Non-Superior to SSRI Therapy

Repetitive TMS for Parkinson Disease Depression Non-Superior to SSRI Therapy

By

The studies that included neurocognitive measures demonstrated no significant difference between the use of rTMS and sham-rTMS.

<i>LRP10</i> Gene Variants Implicated in Parkinson Disease, Lewy Body Dementia

LRP10 Gene Variants Implicated in Parkinson Disease, Lewy Body Dementia

By

Mutations in the LRP10 gene appear to be common in patients with inherited α-synucleinopathies.

Changes in Glucose Regulation in Parkinson Disease

Changes in Glucose Regulation in Parkinson Disease

By

Investigators sought to determine whether patients with moderate to advanced Parkinson disease have impaired glucose levels during an Oral Glucose Tolerance Test.

Parkinson Disease Prevalence Severely Underestimated: Parkinson's Foundation Prevalence Project

Parkinson Disease Prevalence Severely Underestimated: Parkinson's Foundation Prevalence Project

By

The Parkinson's Foundation Prevalence Project estimates that within the next 2 years, 930,000 people in the United States will be living with the condition; that number is anticipated to rise to 1.2 million by 2030.

Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease

Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease

By

Investigators sought to determine if the ECAS diagnostic screening tool is sufficiently sensitive to distinguish between progressive supranuclear palsy and Parkinson disease.

Exercise Does Not Impact Gait or Signal Changes in Freezing and Nonfreezing Parkinson Disease

Exercise Does Not Impact Gait or Signal Changes in Freezing and Nonfreezing Parkinson Disease

By

Study investigators enrolled a total of 37 patients with PD who had participated in a larger prospective, controlled exercise study.

FDA Approves New Pimavanserin Formulation, Dosage Strength

FDA Approves New Pimavanserin Formulation, Dosage Strength

By

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

Strong Link Identified Between T2DM and Parkinson Disease

Strong Link Identified Between T2DM and Parkinson Disease

There is an increased rate of subsequent Parkinson disease among individuals diagnosed with type 2 diabetes mellitus.

Parkinson's Medications Tied to Impulse Control Disorders

Parkinson's Medications Tied to Impulse Control Disorders

For patients with Parkinson disease, dopamine agonist use is associated with incidence of impulse control disorders in a dose-effect relationship.

Focal Brain Atrophy Predicts Cognitive Decline in Parkinson Disease After DBS

Focal Brain Atrophy Predicts Cognitive Decline in Parkinson Disease After DBS

By

A total of 42 consecutive patients with PD who underwent STN-DBS were enrolled in this study.

FDA to Review Sublingual Tx for Motor Fluctuations in Parkinson Disease

FDA to Review Sublingual Tx for Motor Fluctuations in Parkinson Disease

By

Sunovion announced that the FDA has accepted the NDA for apomorphine sublingual film to treat motor fluctuations seen in patients with Parkinson's.

Disrupted Thalamo-Striato-Hypothalamic Function May Serve as a Good Biomarker for Parkinson Disease

Disrupted Thalamo-Striato-Hypothalamic Function May Serve as a Good Biomarker for Parkinson Disease

By

Investigators tested functional connectivity between the right and left hypothalamus as well as the other brain regions by using the seed-to-voxel strategy.

The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies

The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies

By

More than half of patients diagnosed with Parkinson disease experience freezing of gait.

Emerging Innovations in Parkinson Disease Treatment: Q&A With Dr Matthew Brodsky

Emerging Innovations in Parkinson Disease Treatment: Q&A With Dr Matthew Brodsky

By

Surgical interventions for Parkinson disease are experiencing a swell in innovation, thanks in part to the entry of two additional medical device companies into a field previously dominated by one company.

Sign Up for Free e-newsletters



CME Focus